Abstract
Integrated health-system specialty pharmacies (IHSSP) have shown high medication access, adherence, and provider satisfaction. The goal of this study was to explore healthcare providers’ experiences with specialty medications distributed via Limited Distribution Networks (LDN) that do not include IHSSPs. We investigated healthcare providers’ perceived impact of LDNs on clinic workflow, clinical practice, and patient outcomes. Interviews and focus groups were conducted with fourteen healthcare providers from four outpatient specialty clinics at an academic health system with an IHSSP. Qualitative analysis using an iterative inductive/deductive approach of coded transcripts was used to identify themes. Participants discussed requirements and barriers to communicating with insurance providers, drug manufacturers, and external pharmacies; time and effort required to navigate LDNs and impact on workload and clinic workflow; financial awareness of medication costs and methods for communication about financial information with patients; and advocating for patients to ensure access to necessary therapy and avoid missed doses or treatment lapse. Participants reported barriers to navigating LDNs that can interfere with clinic workflow and patient care. IHSSPs may reduce clinic burden by helping patients access, afford, and remain on therapy.
Publisher
Public Library of Science (PLoS)
Reference26 articles.
1. Limited distribution networks stifle competition in the generic and biosimilar drug industries;L Karas;Am J Manag Care,2018
2. Financial Effect of a Drug Distribution Model Change on a Health System;EM Turingan;Hosp Pharm,2017
3. Restricted drug distribution programs;MP Gabay;Am J Health Syst Pharm,2003
4. Modeling specialty medicine access: Understanding key health system processes and players;J Cocohoba;J Am Pharm Assoc,2019
5. Provider and patient burdens of obtaining oral anticancer medications;DM Geynisman;Am J Manag Care,2018
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献